Savara SVRA
Savara FY 2022: net loss $38.1M; diluted EPS −$0.25
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0000950170-23-010967
- Document
- 10-K
Key figures from this report
These are the numbers Savara reported for the year ended Dec 31, 2022, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Net income−$38.1MAgainst −$43.0M in FY 202110-K income statement, on EDGAR
- Diluted EPS−$0.25Against −$0.32 in FY 202110-K income statement, on EDGAR
- Cash and cash equivalents$52.1M+53% from $34.0M in FY 2021Cash and equivalents only; the company page adds short-term investments.10-K balance sheet, on EDGAR
- Cash from operations−$34.6MAgainst −$40.1M in FY 202110-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Opko Health OPK public float $540M, Dec 31, 2025
- Iovance Biotherapeutics IOVA public float $535M, Jun 30, 2025
- Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025
- Xencor XNCR public float $556M, Jun 30, 2025
- Evolus EOLS public float $560M, Jun 30, 2025
